Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.
Maudy WalravenMarjolein Y V HomsAstrid A M van der VeldtHenk DekkerJose KoldenhofRichard HoneywellArjan D BarendrechtSilvie A E SebastianNaomi ParrArnold C KoekmanEmile E VoestMark RoestSuzanne J A KorporaalHenk M W VerheulPublished in: Angiogenesis (2018)
Sunitinib significantly inhibits platelet aggregation in patients already after 24 h of first administration, whereas bevacizumab had no effect on aggregation. These findings may explain the clinically observed bleedings during treatment with antiangiogenic TKIs.